Fanconi anemia is a dubious disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging, laboratory testing and pathological activation.
A platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Individualised development of treatment plans for the treatment and management of Fanconi anemia usually includes drug therapy, rehabilitation intervention, and regular follow-up to multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Fanconi anemia. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.